Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan (5‑HT1B/1D receptor agonist) presented as an injection for subcutaneous use. The EU‑market product is manufactured under strict quality standards and is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable access to this medication across multiple regions, adhering to import regulations and cold‑chain requirements where applicable.

Imigran (sumatriptan) is used within the triptan class to treat acute migraine episodes.

- Migraine with aura: provides rapid relief of headache pain and associated symptoms. - Migraine without aura: reduces attack duration and severity when administered early. - Acute episodic migraine: aborts attacks and improves functional ability during an episode.

Common and serious adverse reactions have been reported with sumatriptan injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Tingling or numbness: transient paresthesia in the face or extremities. - Flushing: warm sensation and reddening of the skin. - Chest pressure: mild, non‑cardiac chest discomfort. - Nausea: occasional upset stomach. - Dizziness: brief light‑headedness.

Serious or Rare Side Effects: - Coronary vasospasm: constriction of coronary arteries that may cause chest pain. - Myocardial infarction: rare heart attack, especially in patients with cardiovascular disease. - Severe hypertension: sudden high blood pressure episodes. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stroke: rare cerebrovascular event.

Before prescribing Imigran, clinicians should consider several safety precautions.

- Cardiovascular disease: avoid use in patients with ischemic heart disease, uncontrolled hypertension, or history of stroke. - Hemiplegic or basilar migraine: contraindicated due to risk of cerebrovascular events. - Concomitant serotonergic drugs: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Age considerations: not recommended for children or adolescents under 18 years. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sumatriptan may interact with other medicines, requiring avoidance or close monitoring.

Major Interactions (Avoid): - MAO inhibitors: combined use can precipitate severe hypertension or serotonin syndrome. - Other triptans or ergot derivatives: increase risk of vasospasm and serious cardiovascular events. - SSRIs, SNRIs, or other serotonergic agents: heightened potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may increase plasma concentrations of sumatriptan. - Antihypertensive agents: monitor blood pressure for additive effects. - Oral contraceptives: may slightly elevate risk of cardiovascular side effects.